Pharmacist-Led Interventions to Increase Access to Medications for Opioid Use Disorders (PLI-MOUD)
NCT ID: NCT05776823
Last Updated: 2025-09-05
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
NA
267 participants
INTERVENTIONAL
2023-05-05
2026-03-17
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Peer-Delivered Behavioral Activation for Methadone Adherence - Pilot Phase
NCT04248933
The MOUD Plus Pilot: Counseling and Peer Support to Support Retention for Medically Complex Patients With Opioid Use Disorder Seen In Primary Care
NCT06837662
Innovatively Increasing PCP Prescribing of Buprenorphine: Measurement Based Care and Integrated Electronic Solution
NCT04059016
Peer Recovery Support Services for Individuals in Recovery Residences on MOUD
NCT05616949
Pilot Testing a Novel Remotely Delivered Intensive Outpatient Program for Individuals With OUD
NCT05817825
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
1. To increase understanding of racial/ethnic differences in the prevalence of OUD.
2. To test if a pharmacist-led intervention is more effective than a substance use counselor (lay person) in increasing knowledge and confidence among different racial/ethnic groups related to administering Narcan nasal spray in an opioid overdose situation.
3. To test if a pharmacist-delivered an evidence-based intervention, q brief intervention and referral to treatment (BIRT) versus standard medication counseling (SMC) is more effective in increasing access to MOUD.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Pharmacist Narcan Training
Pharmacist-led intervention
Pharmacist Narcan Training
A 20-45-minute didactic presentation conducted with a skills training component designed to demonstrate appropriate administration of the Narcan nasal spray.
Substance Use Counselor Narcan Training
Non-clinician intervention
Substance Use Counselor Narcan Training
A 20-45-minute didactic presentation conducted with a skills training component designed to demonstrate appropriate administration of the Narcan nasal spray.
Brief Intervention and Referral to Treatment (BIRT)
BIRT intervention
BIRT
BIRT participants will receive a 30-45-minute session delivered by the pharmacist to introduce and encourage treatment options, MOUD information, OUD information, and treatment facility information (i.e., flyers (RDD study/CAST clinic/State Opioid Response III funded agencies) and educational materials), and a referral to treatment/linkage to service providers.
Standard Medication Counseling (SMC)
SMC intervention
SMC
SMS participants will receive a 5-10-minute counseling session delivered by the pharmacist providing MOUD information, OUD information, and treatment facility information (i.e., flyers (RDD study/CAST clinic/State Opioid Response III funded agencies) and educational materials).
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Pharmacist Narcan Training
A 20-45-minute didactic presentation conducted with a skills training component designed to demonstrate appropriate administration of the Narcan nasal spray.
BIRT
BIRT participants will receive a 30-45-minute session delivered by the pharmacist to introduce and encourage treatment options, MOUD information, OUD information, and treatment facility information (i.e., flyers (RDD study/CAST clinic/State Opioid Response III funded agencies) and educational materials), and a referral to treatment/linkage to service providers.
SMC
SMS participants will receive a 5-10-minute counseling session delivered by the pharmacist providing MOUD information, OUD information, and treatment facility information (i.e., flyers (RDD study/CAST clinic/State Opioid Response III funded agencies) and educational materials).
Substance Use Counselor Narcan Training
A 20-45-minute didactic presentation conducted with a skills training component designed to demonstrate appropriate administration of the Narcan nasal spray.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* a Re-Entry program participant 7-14 days from release from carceral setting
* provide collateral contact information for ≥2 persons (to ensure consistent contact/follow up)
* have a reliable landline or mobile phone to be contacted by pharmacist
* plan to remain in the Little Rock area for at least 6 months
* able to read and write English
* able to provide informed consent
* possesses manual dexterity; physical ability to roll a person onto her/his/their back and side
* have no allergy to naloxone hydrochloride (active ingredient in Narcan nasal spray)-
* identified on the RODS screener as positive for OUD.
BIRT/SMC:
* a Re-Entry program participant 7-14 days from release from the carceral setting
* provide contact information for ≥2 persons (to ensure consistent contact/follow -up)
* have a reliable landline or mobile phone to be contacted by pharmacist
* plan to remain in the Little Rock area for at least 6 months
* able to read and write English; able to provide informed consent
* identified with OUD.
Exclusion Criteria
* not a RE-entry program participant
* identified substance use disorders other than OUD
BIRT/SMC:
* not a RE-entry program participant
* identified substance use disorders other than OUD
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Arkansas
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Meghan N Breckling, PharmD
Role: PRINCIPAL_INVESTIGATOR
UAMS
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Pulaski County Regional Detention Center
Little Rock, Arkansas, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
274818
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.